Summaries of health policy coverage from major news organizations
Bristol-Myers May Seek Approval For Sustiva Successor in 2003
Bristol-Myers Squibb Co. announced Friday that it "may seek approval" of a "longer-acting" successor to DuPont's Sustiva, if its $7.8 billion buyout of the latter company's pharmaceutical division is approved, Reuters reports. Bristol-Myers would not seek approval for the drug until 2003 and does not have any plans to seek U.S. approvals for any of DuPont's other experimental drugs in 2002 (Reuters, 6/8). Sustiva is an antiretroviral drug used in combination with other AIDS drugs. DuPont sales of Sustiva totaled $386 million last year. Bristol-Myers and DuPont announced on Thursday the planned sale of DuPont's pharmaceutical division, which also has two other AIDS drugs in development (Kaiser Daily HIV/AIDS Report, 6/8).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.